Therapeutic potential of90Y- and131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: A Monte Carlo-based dosimetric analysis

Journal of Nuclear Medicine

Volumn 48, Issue 1, 2007, Pages 150-157

  Song, Hong ^a   Du, Yong ^a   Sgouros, George ^a   Prideaux, Andrew ^a   Frey, Eric ^a   Wahl, Richard L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

131I; 90Y; Dosimetry; Monte Carlo; Non Hodgkin's lymphoma; Pulmonary metastases

Indexed keywords

IBRITUMOMAB TIUXETAN; TOSITUMOMAB I 131; CD20 ANTIGEN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ARTICLE; CALCULATION; DATA ANALYSIS SOFTWARE; DOSIMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG RETENTION; KINETICS; LUNG METASTASIS; LUNG PARENCHYMA; MONTE CARLO METHOD; NONHODGKIN LYMPHOMA; PHANTOM; PLEURA METASTASIS; PRIORITY JOURNAL; RADIATION ABSORPTION; TUMOR VOLUME; ADULT; BIOSYNTHESIS; COMPUTER PROGRAM; HUMAN; IMAGE QUALITY; IMMUNOLOGY; LUNG TUMOR; MALE; METASTASIS; METHODOLOGY; PATHOLOGY; RADIOIMMUNOTHERAPY; RADIOMETRY; SCINTISCANNING;

ADULT; ANTIGENS, CD20; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MONTE CARLO METHOD; NEOPLASM METASTASIS; PHANTOMS, IMAGING; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; SOFTWARE; YTTRIUM RADIOISOTOPES;

EID: 33847248042     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Berkman N, Breuer R, Kramer MR, Polliack A. Pulmonary involvement in lymphoma. Leuk Lymphoma. 1996;20:229-237.
2. Maturen KE, Blane CE, Strouse PJ, Fitzgerald JT. Pulmonary involvement in pediatric lymphoma. Pediatr Radiol. 2004;34:120-124.
3. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
4. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
5. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
6. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
7. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
8. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
9. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
10. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
11. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
12. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
13. Winter JN, Inwards D, Erwin W, et al. Zevalin dose escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results [abstract]. Blood. 2002;100(suppl 1):411a.
14. Nademanee A, Molina A, Forman SJ. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2002;100(suppl 1):182a.
15. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
16. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev. 2004;30:165-172.
17. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985-1994.
18. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages for Internal Photon Sources. Oak Ridge, TN: Oak Ridge National Laboratory; 1987:25-26. ORNL/TM-8381.
19. Yoriyaz H, dos Santos A, Stabin MG, Cabezas R. Absorbed fractions in a voxel-based phantom calculated with the MCNP-4B code. Med Phys. 2000;27:1555-1562.
20. Audi G, Wapstra AH. Masses: Q-values and nucleon separation energies - the 1995 update to the atomic mass evaluation. Nucl Phys A. 1995;595:409-480.
21. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
22. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(suppl 1):128S-140S.
23. Norrgren K, Strand SE, Nilsson R, Lindgren L, Sjogren HO. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med. 1993;34:448-454.
24. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
25. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. 2003;63:111-118.
26. Stein R, Chen S, Haim S, Goldenberg DM. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer. 1997;80(suppl 12):2636-2641.
27. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001;7:3186-3192.
28. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate. 2004;58:145-155.
29. 186Re. J Nucl Med. 2004;45:327-337.
30. 131I. J Nucl Med. 2001;42:967-974.
31. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45:1224-1232.
32. Sharkey RM, Blumenthal RD, Behr TM, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer. 1997;72:477-485